Paul Edick Net Worth

The estimated Net Worth of Paul R Edick is at least $10.9 Million dollars as of 9 August 2023. Mr. Edick owns over 10,000 units of Xeris Biopharma Inc stock worth over $6,543,863 and over the last 13 years he sold XERS stock worth over $0. In addition, he makes $4,307,640 as Chairman of the Board and Chief Executive Officer at Xeris Biopharma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Edick XERS stock SEC Form 4 insiders trading

Paul has made over 11 trades of the Xeris Biopharma Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of XERS stock worth $23,800 on 9 August 2023.

The largest trade he's ever made was buying 200,000 units of Xeris Biopharma Inc stock on 11 November 2021 worth over $416,000. On average, Paul trades about 12,471 units every 49 days since 2011. As of 9 August 2023 he still owns at least 2,288,064 units of Xeris Biopharma Inc stock.

You can see the complete history of Mr. Edick stock trades at the bottom of the page.

Paul Edick biography

Paul Raymond Edick serves as Chairman of the Board, Chief Executive Officer of the Company. Prior to XERIS Pharmaceuticals, Mr. Edick was Founding Partner of 3G Advisors, a consultancy to the pharmaceutical, healthcare and healthcare investor communities. From 2010 to 2014, Mr. Edick was the Chief Executive Officer of Durata Therapeutics (Nasdaq: DRTX), a biopharmaceutical company addressing the growing need for new antibiotics to treat infectious diseases. Durata was acquired by Actavis plc in November 2014. Prior to Durata, Mr. Edick was Chief Executive Office of Ganic Pharmaceuticals, a Warburg Pincus investment search vehicle, from 2008 to 2010. Before Ganic, Mr. Edick was Chief Executive officer of MedPointe Healthcare, Inc., a US-based specialty pharmaceutical company, a position he assumed in 2006, having been President of Pharmaceutical Operations since 2002. Mr. Edick led the growth of the business, the development of a clinical stage portfolio, and the Company was subsequently sold to Meda, AB of Sweden in 2007. Mr. Edick currently serves on the Board of Directors for NewLink Genetics Inc. (Nasdaq: NLNK), Sucampo Pharmaceuticals (Nasdaq: SCMP), Neos Therapeutics (Nasdaq: NEOS), and PDL BioPharma (Nasdaq: PDLI). Mr. Edick has also previously served on a number of pharmaceutical and healthcare company boards including Circassia Pharmaceuticals Plc (London: CIR.L), Amerita Inc. and Informed Medical Communications. He was also Chairman of the Board of Life Cycle Pharma Ltd (fka Veloxis). Mr. Edick holds a Bachelor of Arts in Psychology from Hamilton College.

What is the salary of Paul Edick?

As the Chairman of the Board and Chief Executive Officer of Xeris Biopharma Inc, the total compensation of Paul Edick at Xeris Biopharma Inc is $4,307,640. There are no executives at Xeris Biopharma Inc getting paid more.

How old is Paul Edick?

Paul Edick is 63, he's been the Chairman of the Board and Chief Executive Officer of Xeris Biopharma Inc since 2020. There are 3 older and 16 younger executives at Xeris Biopharma Inc. The oldest executive at Xeris Biopharma Holdings Inc is Jeffrey Sherman, 65, who is the Independent Director.

What's Paul Edick's mailing address?

Paul's mailing address filed with the SEC is C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL, 60607.

Insiders trading at Xeris Biopharma Inc

Over the last 6 years, insiders at Xeris Biopharma Inc have traded over $2,845,230 worth of Xeris Biopharma Inc stock and bought 2,912,235 units worth $31,442,123 . The most active insiders traders include Group, Llc Green Jeremy Red..., James E Deerfield Mgmt L.P...., and Garheng Kong. On average, Xeris Biopharma Inc executives and independent directors trade stock every 46 days with the average trade being worth of $197,048. The most recent stock trade was executed by John P. Schmid on 12 August 2024, trading 4,515 units of XERS stock currently worth $10,159.

What does Xeris Biopharma Inc do?

xeris aspires to break through this restraint by developing ultra-low volume, ready-to-use biotherapeutics delivered through patient-friendly injectable devices. products built on our xeriject technologies could potentially ease the pain of injections for hundreds of millions of patients.

Complete history of Mr. Edick stock trades at Neos Therapeutics Inc, Lumos Pharma Inc, PDL Biopharma Inc, Iterum Therapeutics Plc, Xeris Biopharma Inc, and Milestone Pharmaceuticals Inc

Xeris Biopharma Inc executives and stock owners

Xeris Biopharma Inc executives and other stock owners filed with the SEC include:

• Paul Edick,
  Chairman of the Board, Chief Executive Officer
• John Shannon,
  President, Chief Operating Officer
• Paul R. Edick,
  Chairman & CEO
• Barry Deutsch,
  Chief Financial Officer
• John P. Shannon,
  Pres, COO & Director
• Beth Hecht,
  Senior Vice President, General Counsel, Corporate Secretary
• Beth P. Hecht J.D.,
  Sr. VP, Gen. Counsel, Corp. Sec. & Director
• John Schmid,
  Lead Independent Director
• BJ Bormann,
  Independent Director
• Marla Persky,
  Independent Director
• Jeffrey Sherman,
  Independent Director
• Dawn Halkuff,
  Independent Director
• Mark Thierer,
  Independent Director
• Kenneth Johnson,
  Senior Vice President, Clinical Development, Regulatory, Quality Assurance and Medical Affairs
• Steven Prestrelski,
  Co-Founder, Chief Scientific Officer
• Dr. Steven J. Prestrelski MBA, Ph.D.,
  Co-Founder & Chief Scientific Officer
• Kevin McCulloch,
  Sr. VP of Global Operations & Bus. Devel.
• Dr. Kenneth E. Johnson Pharm. D., Pharm.D.,
  Sr. VP of Clinical Devel., Regulatory, Quality Assurance & Medical Affairs
• Barry M. Deutsch,
  Exec. Officer
• Allison Wey,
  Sr. VP of Investor Relations & Corp. Communications
• Steven M. Pieper,
  Chief Financial Officer
• Dr. Steven J. Prestrelski,
  Co-Founder & Chief Scientific Officer
• Group, Llc Green Jeremy Red...,
  
• James E Deerfield Mgmt L.P....,
  
• Partners, Ltd.Palmetto Part...,
  
• Barbara Jean Anne Bormann K...,
  Director
• Jonathan Rigby,
  Director
• Kevin Mc Culloch,
  See Remarks
• Steven Pieper,
  See Remarks
• John Johnson,
  Director
• Garheng Kong,
  Director
• Ricki Louise Fairley,
  Director